The shortage of new antibiotics increases the fear "Resurrection Day"

The World Health Organization said in a recent report that only 12 new antibiotics entered the market between 2017 and 2021, and warning about the “day of resurrection” scenario, as routine medical procedures will not be effective in treating what is known as “simple infection”. The report, which will be offered a special session for the European Conference on Clinical Biology and Infectious Diseases in Denmark next April, pointed out that a small number is no more than 27 antibiotics still developed in clinical trials against pathogens, which the world organization considers “critical”. In the five years covered by this report, scientists created 12 accredited antibiotics, with only one kind called “Cevidroke” capable of targeting all pathogens that the organization considers “critical”. Among the 27 antagonists, only six “innovative” are considered enough to overcome antibiotic resistance using the standards of the World Health Organization, and of only six 2 the target on the bacterial forms of antibiotics with high resistance. About 5 million deaths are linked annually to the resistance to bacteria against antibiotics, but the actual burden of resistance can be greater. In addition, antimicrobial resistance is incompatible against poor individuals who only get a few antibiotics from the second and most expensive line that can work if the first rule medication fails. The production of “inadequate” and without effective antibiotics dies countless people due to a “simple infection” that can be treated, as experts have said that the current antibacterial production line “is unlucky enough” to create a difference in addressing the constant threat to resist antibiotics as a result of the world’s lack of a sustainable economic model for antibacterial innovation. Scientists have emphasized that the problem is exacerbated, as the current evaluating products meet mainly the requirements of developed countries, which can lead to the spread of antibiotic resistance in developing countries that already provide a major burden of resistance. Bacteria resistance to antibiotics, which means that these drugs do not become effective against bacteria, due to excessive uncertainty, such as the failure of people to complete the complete cycle of antibiotics or as a result of the description of incorrect antibiotics. Antibiotics are widely used in some countries without prescriptions. 27 anti -development and drew the report in the three stages of clinical tests only 27 anti -development, most of which are not entirely new categories, but only a development of the existing groups. Antibiotics are not considered profitable medicines as other treatments for pharmaceutical businesses because they are mostly treatments taken for short periods, and doctors do not easily prescribe them, especially not in developed countries as they keep it in treatment as a last option. The research and development process for new antibiotics faces the challenge of poor financing. The latest new antibiotic category was discovered in the 1980s, and the first antibiotic from this category, “Diptomycin”, reached the market in 2003. Scientists say that the rapid increase in the infection of multiple drugs around the world is ‘worrying’, pointing out that time is a new threat to public health. Without acting immediately, scientists say that we ‘go back to the pre -antibiotic era’ as the general infection becomes deadly. Also read: